Orphazyme AS (CHIX:ORPHAC) EBIT per Share : kr-16,912.63 (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS EBIT per Share?

Orphazyme AS's EBIT per Share for the six months ended in Jun. 2022 was kr-778.26. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 was kr-16,912.63.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Orphazyme AS's EBIT per Share or its related term are showing as below:

CHIX:ORPHAc's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Orphazyme AS's EBIT for the six months ended in Jun. 2022 was kr-27.24 Mil.

Orphazyme AS EBIT per Share Historical Data

The historical data trend for Orphazyme AS's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS EBIT per Share Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT per Share

Get a 7-Day Free Trial

-10,918.00

-11,613.80

-16,909.70

-22,180.25

-17,772.06

Orphazyme AS Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EBIT per Share	Get a 7-Day Free Trial									-9,817.16	-13,414.93	-1,637.69	-16,134.37	-778.26

Orphazyme AS EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Orphazyme AS's EBIT per Share for the fiscal year that ended in Dec. 2021 is calculated as

	EBIT per Share		(A: Dec. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-622.022	/	0.035
=	-17,772.06

Orphazyme AS's EBIT per Share for the quarter that ended in Jun. 2022 is calculated as

	EBIT per Share		(Q: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-27.239	/	0.035
=	-778.26

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-16,912.63

Orphazyme AS (CHIX:ORPHAc) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Orphazyme AS EBIT per Share Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS Headlines

No Headlines